Athena asks for rehearing on invalidated neurological disorder patent

Athena Diagnostics has asked the US Federal Circuit to revisit its decision earlier this year, which found four claims in one of its patents to be invalid.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Companies file amicus brief opposing Athena ruling

25 April 2019 Biotech and pharmaceutical companies have submitted an amicus brief urging an appeals court to rethink a ruling, which invalidated a patent exclusively licensed by Athena Diagnostics.

Biotechnology

Victory for Mayo in neurological disorder patent dispute

7 February 2019 In a victory for Mayo Collaborative Services, a US Court has ruled that four claims in a patent, of which Athena Diagnostics is the exclusive licensee, are invalid.

More features

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

Athena asks for rehearing on invalidated neurological disorder patent

More on this story

Editor's picks

Editor's picks

More features